Axial Biotherapeutics to Participate in Upcoming Conferences in June
WALTHAM, Mass.--(BUSINESS WIRE)-- Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will participate in the following conferences in June:
-
BIO International Convention 2019 on Monday, June 3, 2019 at
3:00 p.m. ET in Philadelphia, PA
- Panel Presentation: What’s Next: The Landscape of Innovation in 2019 and Beyond
- Session ID: 537703
-
CNS Targets and Translational Strategies on Wednesday, June 19,
2019 at 8:05 a.m. ET in Boston, MA
- Presentation: Harnessing the Gut-Brain Axis to Discover Novel CNS Therapeutics
- JMP Securities Life Sciences Conference on Thursday, June 20, 2019 at 11:30 a.m. ET in New York, NY
About Axial Biotherapeutics
Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005157/en/
Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Source: Axial Biotherapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Understanding Lymph System Support Supplements: PureHealth Research Highlights Natural Ingredients for Everyday Wellness
- Kurly Expands Its Chef-Driven Food Collection with Udon Kaden's U.S. Retail Launch
- Beyond Backyard Living Adds Fixed-Price Pools and Outdoor Kitchens
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share